<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02604485</url>
  </required_header>
  <id_info>
    <org_study_id>X358602</org_study_id>
    <nct_id>NCT02604485</nct_id>
  </id_info>
  <brief_title>A Single-Dose Open-Label Study of XOMA 358 in Subjects With Congenital Hyperinsulinism</brief_title>
  <official_title>A Single-Dose Open-Label Study of XOMA 358 in Subjects With Congenital Hyperinsulinism (HI)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>XOMA (US) LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>XOMA (US) LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and clinical pharmacology of a single
      dose pharmacokinetics and pharmacodynamics of XOMA 358 in subjects with hypoglycemia
      associated with congenital hyperinsulinism.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Actual">January 2017</completion_date>
  <primary_completion_date type="Actual">January 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment-emergent adverse events</measure>
    <time_frame>42 days</time_frame>
    <description>Safety assessed by treatment-emergent adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in glucose levels as measured using a continuous glucose monitor</measure>
    <time_frame>42 days</time_frame>
    <description>Safety assessed by pre- and post-treatment measurements of vital signs and laboratory test results</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fasting and post prandial blood glucose levels</measure>
    <time_frame>42 days</time_frame>
    <description>Assessment of blood glucose collected at time points specified in the protocol</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Congenital Hyperinsulinism</condition>
  <arm_group>
    <arm_group_label>Cohort</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>XOMA 358 dose level A, dose level B, dose level C, and dose level D.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cohort 1</intervention_name>
    <description>XOMA 358 single dose level A administered by an intravenous infusion</description>
    <arm_group_label>Cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cohort 2</intervention_name>
    <description>XOMA 358 single dose level B administered by an intravenous infusion</description>
    <arm_group_label>Cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cohort 3</intervention_name>
    <description>XOMA 358 single dose level C administered by an intravenous infusion</description>
    <arm_group_label>Cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cohort 4</intervention_name>
    <description>XOMA 358 single dose level D administered by an intravenous infusion</description>
    <arm_group_label>Cohort</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of congenital hyperinsulinism

          -  Duration of glucose levels less than 70mg/dL, by CGM, for an average of at least 120
             minutes a day across baseline Days -3, -2, and -1 with no single duration less than 60
             minutes on any of the baseline Days -3, -2, or -1, unless the subject received rescue
             treatment.

          -  Can safely washout of background medications used to treat hyperinsulinism.

        Exclusion Criteria:

          -  Use of any agent, such as diazoxide, octreotide, chronic systemic glucocorticoids, or
             β agonists that may affect glucose metabolism

          -  Body Mass Index ≥ 35 kg/m2

          -  Pregnant females, females planning to become pregnant during the course of the study,
             females who have delivered 3 months before screening, or breastfeeding

          -  Male subjects who are planning a pregnancy with a female partner during the course of
             the study or within 4 months after administration of study drug.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Allan Gordon, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>XOMA (US) LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 26, 2015</study_first_submitted>
  <study_first_submitted_qc>November 10, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 13, 2015</study_first_posted>
  <last_update_submitted>February 2, 2017</last_update_submitted>
  <last_update_submitted_qc>February 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hypoglycemia</keyword>
  <keyword>Congenital Hyperinsulinism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperinsulinism</mesh_term>
    <mesh_term>Congenital Hyperinsulinism</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

